Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 352807, 9 pages
http://dx.doi.org/10.1155/2012/352807
Research Article

Activation of Peroxisome Proliferator-Activated Receptor by Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1

1Department of Animal Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
2Department of Nursing, Semyung University, Jecheon 390-711, Republic of Korea
3Department of Applied Bioscience, College of Life Science, CHA University, Seongnam 463-712, Republic of Korea

Received 31 August 2012; Revised 27 November 2012; Accepted 29 November 2012

Academic Editor: Kuen-Jer Tsai

Copyright © 2012 Jung Seok Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Figure 1: Effects of PPAR ligands on cell viability. RAW264.7 cells were incubated with various concentrations of WY-14643 (a specific agonist for PPARα), GW501516 (a specific agonist for PPARσ), or rosiglitazone (a specific agonist for PPARγ) for 24 h. Cells were then washed with ice-cold PBS, harvested, and mixed with a 0.4% trypan blue solution. Viable cells in the cell suspension were counted using a hemacytometer. Data are expressed as the means±SE (n=6).

Supplementary Figure 2: Effects of rosiglitazone on the LPS-induced release of MCP-1, MIP-1β, and TNF-α. RAW264.7 cells grown to 60% confluency were incubated with serum-free medium for 24 h and then stimulated with LPS in the presence or absence of rosiglitazone for 24 h. Equal volumes of conditioned media were subjected to Western blot analysis. Ponceau S staining was used as a loading control.

Supplementary Figure 3: Effects of rosiglitazone on the expression of iNOS. RAW264.7 cells were grown to 60% confluency incubated with serum-free medium for 24 h and then stimulated with LPS in the presence or absence of rosiglitazone for 24 h. Total protein was extracted, fractionated by electrophoresis, and immunoblotted using an iNOS antibody.

  1. Supplementary Figures